NASDAQ: CMPX
Compass Therapeutics Inc Stock

$1.84-0.06 (-3.16%)
Updated Apr 29, 2025
CMPX Price
$1.84
Fair Value Price
$0.18
Market Cap
$254.44M
52 Week Low
$0.77
52 Week High
$4.08
P/E
-5.11x
P/B
2.03x
P/S
234.36x
PEG
N/A
Dividend Yield
N/A
Revenue
$850.00k
Earnings
-$49.38M
Gross Margin
100%
Operating Margin
-5,808.82%
Profit Margin
-5,808.8%
Debt to Equity
0.12
Operating Cash Flow
-$45M
Beta
0.94
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CMPX Overview

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat multiple human diseases. Its product candidates include CTX-009, in Phase II clinical trials for biliary tract cancers and Phase Ib clinical trial for colorectal and ovarian cancer, and CTX-471, in Phase I clinical trials for patients with solid tumors (small cell lung cancer and melanoma). Compass Therapeutics was founded in 2014 and is headquartered in Boston, MA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine CMPX's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
CMPX
Ranked
#257 of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important CMPX news, forecast changes, insider trades & much more!

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CMPX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CMPX ($1.84) is overvalued by 939.03% relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CMPX ($1.84) is not significantly undervalued (939.03%) relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CMPX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CMPX due diligence checks available for Premium users.

Valuation

CMPX fair value

Fair Value of CMPX stock based on Discounted Cash Flow (DCF)

Price
$1.84
Fair Value
$0.18
Overvalued by
939.03%
CMPX ($1.84) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CMPX ($1.84) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CMPX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CMPX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-5.11x
Industry
-158.75x
Market
29.19x

CMPX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.03x
Industry
4.37x
CMPX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CMPX's financial health

Profit margin

Revenue
$0.0
Net Income
-$15.0M
Profit Margin
0%
CMPX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CMPX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$140.4M
Liabilities
$15.2M
Debt to equity
0.12
CMPX's short-term assets ($132.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CMPX's short-term assets ($132.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CMPX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CMPX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$9.2M
Investing
$15.4M
Financing
-$94.0k
CMPX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CMPX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
CMPXD$254.44M-3.16%-5.11x2.03x
MNPRD$256.48M+2.82%-10.21x4.66x
AVIRD$252.30M-0.34%-1.48x0.57x
IMMPC$251.82M+4.85%-8.32x2.32x
ABEOC$257.23M-0.93%-3.42x5.84x

Compass Therapeutics Stock FAQ

What is Compass Therapeutics's quote symbol?

(NASDAQ: CMPX) Compass Therapeutics trades on the NASDAQ under the ticker symbol CMPX. Compass Therapeutics stock quotes can also be displayed as NASDAQ: CMPX.

If you're new to stock investing, here's how to buy Compass Therapeutics stock.

What is the 52 week high and low for Compass Therapeutics (NASDAQ: CMPX)?

(NASDAQ: CMPX) Compass Therapeutics's 52-week high was $4.08, and its 52-week low was $0.77. It is currently -54.9% from its 52-week high and 140.52% from its 52-week low.

How much is Compass Therapeutics stock worth today?

(NASDAQ: CMPX) Compass Therapeutics currently has 138,282,498 outstanding shares. With Compass Therapeutics stock trading at $1.84 per share, the total value of Compass Therapeutics stock (market capitalization) is $254.44M.

Compass Therapeutics stock was originally listed at a price of $3.55 in Nov 3, 2021. If you had invested in Compass Therapeutics stock at $3.55, your return over the last 3 years would have been -48.17%, for an annualized return of -19.67% (not including any dividends or dividend reinvestments).

How much is Compass Therapeutics's stock price per share?

(NASDAQ: CMPX) Compass Therapeutics stock price per share is $1.84 today (as of Apr 29, 2025).

What is Compass Therapeutics's Market Cap?

(NASDAQ: CMPX) Compass Therapeutics's market cap is $254.44M, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Compass Therapeutics's market cap is calculated by multiplying CMPX's current stock price of $1.84 by CMPX's total outstanding shares of 138,282,498.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.